- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COA 2019: On Location Interviews, Day 2
On day 2 of the Community Oncology Alliance's annual Community Oncology Conference, held April 4-5 in Orlando, Florida, we spoke with Debra Patt, MD, MPH, MBA, executive vice president of Texas Oncology, and Jeffrey Vacirca, MD, chief executive officer of New York Cancer & Blood Specialists.
Today, we are on site for day 2 of the Community Oncology Alliance’s annual Community Oncology Conference in Orlando, Florida!
We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Debra Patt, MD, vice president of Texas Oncology, and Jeff Vacirca, MD, of New York Cancer & Blood Specialists.
Welcome to AJMC® on location, I’m Jaime Rosenberg!
The second day of the meeting focused on cancer drugs and different strategies for addressing their cost. There was a session on chimeric antigen receptor T-cell therapy, which explored different clinical and reimbursement challenges associated with the treatment. In addition, there were sessions on the adverse impact pharmacy benefit managers have on cancer care, and the effect of step therapy and utilization management on access to cancer treatments. We also got an industry perspective on price, cost, and value of cancer drugs.
Read coverage and watch additional interviews.
That’s all from COA's Annual Community Oncology Conference. Join us again May 19-21, when we will be reporting on site at The International Society for Pharmacoeconomics and Outcomes Research’s annual meeting being held in New Orleans, Louisiana.
Thank you for watching AJMC® News Network! I’m Jaime Rosenberg.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
